Dear Friends and Investors:

Please join us for a special virtual private investor meeting on Friday, December 1st at 11:00 AM EST featuring American Gene Technologies International (“AGT”), one of the most exciting companies we have seen.

AGT recently announced a merger agreement for a business combination with 10X Capital Venture Acquisition Corp. III (“10X III”) (NYSE American: VCXB), a special purpose acquisition company. The resulting combined company will be renamed “Addimmune” and will trade on the NYSE. Addimmune will be a clinical-stage gene and cell therapy company focused on developing a functional cure for HIV. Prior to the combination, the non-HIV assets will spin-off into an entity that will retain the American Gene Technologies name.

COMPANY OVERVIEW

Addimmune will be dedicated to revolutionizing treatments for human immunodeficiency virus (HIV), a disease which currently impacts 5 million individuals across the US and Europe. Addimmune's lead treatment, AGT103-T, is a genetically modified autologous cell product candidate that has the potential to be the first functional cure and a potential best-in-class adjuvant treatment for HIV.

COMPANY ACCOMPLISHMENTS

AGT's HIV business has made significant strides to advance AGT103-T as the world’s first potential functional cure for HIV. Beginning with a collaboration with the National Institute of Allergy and Infectious Disease in 2019, the team has made consistent progress from securing FDA approval of an Investigational Drug Application for and completing a Ph 1a safety and durability study of AGT103-T in 2022. The full data from the Ph 1a study was published in Frontiers in Medicine. Additionally, the team recently shared the pre-print of a follow-on analytic treatment interruption study, which evaluated the impact on HIV-specific immune responses in AGT103-T-infused patients following the cessation of antiretroviral therapy (ART). AGT is currently in the process of submitting those results to a peer-reviewed journal.

FUNDRAISING

AGT is raising up to $50 million through the issue and sale of senior secured convertible notes ("Convertible Note"). The Convertible Note features a 3x liquidation preference and a 36-month maturity period and may be purchased by all accredited investors.

USE OF FUNDS

The Convertible Note financing will be instrumental in initiating the Ph 1b study of AGT103-T, expanding HIV research initiatives, and expediting Addimmune's journey toward potential regulatory approval.

TARGET MARKET

We firmly believe that cell and gene therapy has the potential to disrupt the forthcoming $39.3 billion global HIV therapy market, where currently, payors are investing up to $1.7 million per patient in life-long standard care. Be part of the transformation.

Please join us to learn more about this exciting investment opportunity and exciting technology! If you have any questions or would like any information, such as Executive Summary or Deck, prior to the meeting, please email Skylar Rallison at srallison@opus8.com.

Thanks much and we look forward to seeing you online on December 1st!

All the best,

The Opus8 Team